Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Richard Hamman to Treatment Outcome

This is a "connection" page, showing publications Richard Hamman has written about Treatment Outcome.

 
Connection Strength
 
 
 
0.116
 
  1. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006 Sep; 29(9):2102-7.
    View in: PubMed
    Score: 0.030
  2. Amutha A, Praveen PA, Hockett CW, Ong TC, Jensen ET, Isom SP, D'Agostino RBJ, Hamman RF, Mayer-Davis EJ, Wadwa RP, Lawrence JM, Pihoker C, Kahn MG, Dabelea D, Tandon N, Mohan V. Treatment regimens and glycosylated hemoglobin levels in youth with Type 1 and Type 2 diabetes: Data from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes. 2021 02; 22(1):31-39.
    View in: PubMed
    Score: 0.019
  3. Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC. Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet Med. 2017 12; 34(12):1747-1755.
    View in: PubMed
    Score: 0.016
  4. Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF. Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. Diabet Med. 2014 09; 31(9):1064-8.
    View in: PubMed
    Score: 0.013
  5. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14; 374(9702):1677-86.
    View in: PubMed
    Score: 0.009
  6. Hammermeister KE, Fairclough D, Emsermann CB, Hamman R, Ho M, Phibbs S, Plomondon M, Valuck R, West D, Steiner JF. Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. Clin Ther. 2009 Mar; 31(3):632-43.
    View in: PubMed
    Score: 0.009
  7. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb; 56(2):531-6.
    View in: PubMed
    Score: 0.008
  8. Ratchford AM, Hamman RF, Regensteiner JG, Magid DJ, Gallagher SB, Merenich JA. Attendance and graduation patterns in a group-model health maintenance organization alternative cardiac rehabilitation program. J Cardiopulm Rehabil. 2004 May-Jun; 24(3):150-6.
    View in: PubMed
    Score: 0.006
  9. Molitch ME, Fujimoto W, Hamman RF, Knowler WC. The diabetes prevention program and its global implications. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S103-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)